Home/Iovance Biotherapeutics/Ibrahim El-Houssieny
IE

Ibrahim El-Houssieny

Chief Commercial Officer

Iovance Biotherapeutics

Therapeutic Areas

Iovance Biotherapeutics Pipeline

DrugIndicationPhase
Amtagvi (lifileucel)Advanced Melanoma (post-anti-PD1)Approved
LifileucelAdvanced Non-Small Cell Lung Cancer (NSCLC)Phase 2
TIL + PembrolizumabAdvanced Front-line MelanomaPhase 3